Product Code: ETC6184485 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australias malaria treatment market is expanding, driven by global efforts to eradicate malaria, along with the countrys focus on treatment strategies for travelers and humanitarian projects in malaria-endemic areas. Artemisinin-based combination therapies (ACTs) remain the frontline treatment, while newer drugs and vaccines are being researched to improve efficacy and reduce resistance. The Australian market is also experiencing increased demand for antimalarial drugs used in post-exposure prophylaxis and for treating imported malaria cases. Australias strong healthcare infrastructure and collaborations with international organizations help provide timely access to medications. As treatment strategies evolve, the market is expected to grow, with continuous improvements in drug development and distribution.
Though malaria cases in Australia are limited to travelers and imported instances, the market for antimalarial treatments remains relevant, particularly through public health procurement, travel medicine, and pharmaceutical distribution to neighboring regions. Key treatments include artemisinin-based combination therapies (ACTs), chloroquine, and prophylactic medications for travelers. Australia`s TGA continues to regulate and approve newer antimalarial drugs for availability within the private healthcare system. Demand also exists for pediatric formulations and long-term protection for expatriates and aid workers. Furthermore, Australian researchers are involved in global efforts for drug resistance tracking and therapeutic development, particularly in the Asia-Pacific corridor, strengthening the country`s role in regional health security.
Australias malaria treatment market struggles with the limited availability of new, effective antimalarial drugs due to low domestic demand. Drug resistance trends globally require frequent updates to treatment guidelines, complicating healthcare provider education. Import reliance for essential antimalarial medications can cause shortages and pricing volatility. Public awareness about malaria risk in travelers remains insufficient, resulting in inadequate prophylactic treatment uptake. Research funding for malaria therapies in Australia is minimal compared to global hotspots. Additionally, compliance with treatment regimens can be challenging, especially for long-term travel-related cases.
Australias malaria treatment market, though limited domestically, benefits from its role in supplying therapeutics to endemic regions across the Asia-Pacific. Government funding and partnerships with global health organizations support R&D into antimalarial drugs and resistance management. Investment opportunities exist in the development and export of next-generation treatments, particularly those targeting drug-resistant strains. Australian pharmaceutical firms engaged in tropical disease portfolios can leverage government grants and tax incentives. There is also potential in contract manufacturing of antimalarial drugs. Investors can strategically align with public health programs and NGOs working in malaria hotspots for broader impact.
Australias approach to malaria treatment is centered around prevention and readiness due to its non-endemic status. Antimalarial drugs are regulated by the TGA and are made available under prescription through the Pharmaceutical Benefits Scheme (PBS) for those traveling to or returning from high-risk areas. The government partners with private and academic institutions to research drug-resistant malaria strains and contribute to global treatment protocols. Traveler advisories and vaccination guidelines are issued regularly by the Department of Foreign Affairs and Trade (DFAT). Quarantine policies ensure early detection and prompt treatment of any imported cases. Australia also contributes to regional malaria elimination programs, especially in Papua New Guinea and Southeast Asia.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Malaria Treatment Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Malaria Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Malaria Treatment Market - Industry Life Cycle |
3.4 Australia Malaria Treatment Market - Porter's Five Forces |
3.5 Australia Malaria Treatment Market Revenues & Volume Share, By Agent, 2021 & 2031F |
3.6 Australia Malaria Treatment Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Australia Malaria Treatment Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.8 Australia Malaria Treatment Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.9 Australia Malaria Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Australia Malaria Treatment Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.11 Australia Malaria Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Malaria Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of malaria cases in Australia |
4.2.2 Rising awareness about the importance of timely malaria treatment |
4.2.3 Government initiatives and funding to combat malaria in Australia |
4.3 Market Restraints |
4.3.1 Limited availability of effective malaria treatment options |
4.3.2 High cost associated with malaria treatment |
4.3.3 Potential emergence of drug-resistant malaria strains |
5 Australia Malaria Treatment Market Trends |
6 Australia Malaria Treatment Market, By Types |
6.1 Australia Malaria Treatment Market, By Agent |
6.1.1 Overview and Analysis |
6.1.2 Australia Malaria Treatment Market Revenues & Volume, By Agent, 2021- 2031F |
6.1.3 Australia Malaria Treatment Market Revenues & Volume, By Plasmodium Falciparum, 2021- 2031F |
6.1.4 Australia Malaria Treatment Market Revenues & Volume, By P. Vivax, 2021- 2031F |
6.1.5 Australia Malaria Treatment Market Revenues & Volume, By P. Ovale, 2021- 2031F |
6.1.6 Australia Malaria Treatment Market Revenues & Volume, By P. Malariae, 2021- 2031F |
6.1.7 Australia Malaria Treatment Market Revenues & Volume, By P. Knowlelsi, 2021- 2031F |
6.2 Australia Malaria Treatment Market, By Type |
6.2.1 Overview and Analysis |
6.2.2 Australia Malaria Treatment Market Revenues & Volume, By Medication, 2021- 2031F |
6.2.3 Australia Malaria Treatment Market Revenues & Volume, By Vaccination, 2021- 2031F |
6.3 Australia Malaria Treatment Market, By Treatment |
6.3.1 Overview and Analysis |
6.3.2 Australia Malaria Treatment Market Revenues & Volume, By Suppressive treatment, 2021- 2031F |
6.3.3 Australia Malaria Treatment Market Revenues & Volume, By Radical treatment, 2021- 2031F |
6.4 Australia Malaria Treatment Market, By Drug Type |
6.4.1 Overview and Analysis |
6.4.2 Australia Malaria Treatment Market Revenues & Volume, By Branded, 2021- 2031F |
6.4.3 Australia Malaria Treatment Market Revenues & Volume, By Generics, 2021- 2031F |
6.5 Australia Malaria Treatment Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Australia Malaria Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Australia Malaria Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.6 Australia Malaria Treatment Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 Australia Malaria Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Australia Malaria Treatment Market Revenues & Volume, By Specialty clinics, 2021- 2031F |
6.6.4 Australia Malaria Treatment Market Revenues & Volume, By Home healthcare, 2021- 2031F |
6.7 Australia Malaria Treatment Market, By Distribution Channel |
6.7.1 Overview and Analysis |
6.7.2 Australia Malaria Treatment Market Revenues & Volume, By Direct tender, 2021- 2031F |
6.7.3 Australia Malaria Treatment Market Revenues & Volume, By Hospital pharmacies, 2021- 2031F |
6.7.4 Australia Malaria Treatment Market Revenues & Volume, By Online pharmacies, 2021- 2031F |
6.7.5 Australia Malaria Treatment Market Revenues & Volume, By Online pharmacies, 2021- 2031F |
7 Australia Malaria Treatment Market Import-Export Trade Statistics |
7.1 Australia Malaria Treatment Market Export to Major Countries |
7.2 Australia Malaria Treatment Market Imports from Major Countries |
8 Australia Malaria Treatment Market Key Performance Indicators |
8.1 Number of reported malaria cases in Australia |
8.2 Funding allocated by the government for malaria treatment and prevention programs |
8.3 Adoption rate of new malaria treatment technologies |
8.4 Percentage of the population with access to malaria treatment facilities |
8.5 Success rate of malaria treatment interventions in Australia |
9 Australia Malaria Treatment Market - Opportunity Assessment |
9.1 Australia Malaria Treatment Market Opportunity Assessment, By Agent, 2021 & 2031F |
9.2 Australia Malaria Treatment Market Opportunity Assessment, By Type, 2021 & 2031F |
9.3 Australia Malaria Treatment Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.4 Australia Malaria Treatment Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.5 Australia Malaria Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Australia Malaria Treatment Market Opportunity Assessment, By End User, 2021 & 2031F |
9.7 Australia Malaria Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Malaria Treatment Market - Competitive Landscape |
10.1 Australia Malaria Treatment Market Revenue Share, By Companies, 2024 |
10.2 Australia Malaria Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |